Physician
Tyminska-Paluchowska, Beata
Tyminska-Paluchowska, Beata was paid $1.34M by Medicaid between Jan 2018 and Mar 2023, across 36 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 33% of everything it billed.
33Billing provider infoTYMINSKA-PALUCHOWSKA, BEATA
SPRINGFIELD, MA 01104
SPRINGFIELD, MA 01104
33aNPI1144217449assigned 10/02/2005
33bProvider typePediatric Adolescent Medicine Physician
28Total paid$1.34M
24GClaims37,661
24DCodes billed36
24AFirst – last monthJan 2018 – Mar 2023
Compared with peers
Next to other Pediatric Adolescent Medicine Physician providers in Massachusetts
Rank by total paid#8 of 54
Median peer was paid$119K
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,235 | $254K | |
| 2019 | 8,994 | $278K | |
| 2020 | 5,862 | $220K | |
| 2021 | 6,802 | $252K | |
| 2022 | 7,129 | $278K | |
| 2023 | 1,639 | $63K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 33% | 4,789 | 4,251 | $446K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 20% | 5,125 | 4,726 | $272K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 8.5% | 3,512 | 2,806 | $114K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 5.2% | 829 | 825 | $69K |
| 99177 | 4.1% | 1,632 | 1,625 | $55K | |
| 92587 | 3.9% | 1,728 | 1,717 | $52K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 3.9% | 621 | 620 | $52K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 3.7% | 622 | 598 | $50K |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 2.4% | 3,425 | 3,386 | $32K |
| 90461 | 2.4% | 1,071 | 1,066 | $32K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2.3% | 340 | 340 | $31K |
| 99188 | 2.2% | 1,151 | 1,144 | $30K |
24 more codes
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.7% | 2,150 | $23K |
| 96127 | 1.3% | 1,546 | $17K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 728 | $9K |
| 99401 | <1% | 263 | $8K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 418 | $7K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 207 | $6K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 275 | $6K |
| 81002 | <1% | 1,863 | $5K | |
| 96160 | <1% | 1,158 | $4K | |
| 94760 | <1% | 1,608 | $4K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 37 | $3K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 417 | $3K |
| 99051 | <1% | 159 | $3K | |
| 88738 | <1% | 397 | $2K | |
| 36416 | <1% | 255 | $2K | |
| 83655 | <1% | 121 | $1K | |
| 92567 | <1% | 115 | $1K | |
| 94761 | <1% | 330 | $1K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 42 | $985.53 |
| 85018 | <1% | 382 | $883.20 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 292 | $718.69 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 12 | $615.84 |
| 96161 | <1% | 29 | $111.94 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 12 | $7.37 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.